Also trades as: NUVB (NYSE) · $vol 24M
NUVB-WT NYSE
Nuvation Bio Inc.
1W: -8.1%
1M: +16.5%
3M: +16.6%
YTD: -76.3%
1Y: -69.5%
$0.07
-0.00 (-3.82%)
Weekly Expected Move ±12.9%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$25.2M
52W Range0.0051-0.1444
Volume7,799,099
Avg Volume52,014
Beta2.05
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEODavid T. Hung
Employees220
SectorHealthcare
IndustryBiotechnology
IPO Date2020-08-26
Websitenuvationbio.com
1500 Broadway, Suite 1401
New York, NY 10036
US
New York, NY 10036
US
+1 646 616 2000
About Nuvation Bio Inc.
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
Latest News
Nuvation Bio Inc. Q1 2026 Earnings Call Summary
Brokerages Set Nuvation Bio Inc. (NYSE:NUVB) Target Price at $11.63
Kerry Wentworth Sells 200,000 Shares of Nuvation Bio (NYSE:NUVB) Stock
JPMorgan Chase & Co. Purchases 557,656 Shares of Nuvation Bio Inc. $NUVB
Capricorn Fund Managers Ltd Makes New Investment in Nuvation Bio Inc. $NUVB
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Wentworth Kerry | M-Exempt | 36,750 | $2.93 | 2026-04-17 |
| Wentworth Kerry | M-Exempt | 36,750 | $2.93 | 2026-04-17 |
| Wentworth Kerry | S-Sale | 36,750 | $5.01 | 2026-04-17 |
| Liu Dongfang | M-Exempt | 50,000 | $1.94 | 2026-04-17 |
| Liu Dongfang | M-Exempt | 50,000 | $1.94 | 2026-04-17 |